Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer
Status:
Withdrawn
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the clinical benefit of lapatinib plus trastuzumab
compared to lapatinib plus capecitabine as measured by investigator-assessed progression-free
survival, tumour response and overall survival.
Phase:
Phase 2
Details
Lead Sponsor:
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.